EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SAMHD1 expression contributes to doxorubicin resistance and predicts survival outcomes in diffuse large B-cell lymphoma patients

Waaqo Daddacha iD, Dominique Monroe iD, Ashley J Schlafstein, Allison E Withers, Elizabeth B Thompson, Diana Danelia, Nho C Luong, Fatmata Sesay, Sandip K Rath, Edidiong R Usoro, Mark E Essien, Andrew T Jung und 13 weitere

NAR Cancer · 2024

DOI: 10.1093/narcan/zcae007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NAR Cancer, 2024. Verfasst von Waaqo Daddacha und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA. Hauptthemen laut MEDLINE: Doxorubicin, Lymphoma, Large B-Cell, Diffuse, Drug Resistance, Neoplasm, SAM Domain and HD Domain-Containing Protein 1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B-cell lymphoma (DLBCL) is a commonly diagnosed, aggressive non-Hodgkin's lymphoma. While R-CHOP chemoimmunotherapy is potentially curative, about 40% of DLBCL patients will fail, highlighting the need to identify biomarkers to optimize management. SAMHD1 has a dNTPase-independent role in promoting resection to facilitate DNA double-strand break (DSB) repair by homologous recombination. We evaluated the relationship of SAMHD1 levels with sensitivity to DSB-sensitizing agents in DLBCL cells and the association of SAMHD1 expression with clinical outcomes in 79 DLBCL patients treated with definitive therapy and an independent cohort dataset of 234 DLBCL patients. Low SAMHD1 expression, Vpx-mediated, or siRNA-mediated degradation/depletion in DLBCL cells was associated with greater sensitivity to doxorubicin and PARP inhibitors. On Kaplan–Meier log-rank survival analysis, low SAMHD1 expression was associated with improved overall survival (OS), which on subset analysis remained significant only in patients with advanced stage (III-IV) and moderate to high risk (2–5 International Prognostic Index (IPI)). The association of low SAMHD1 expression with improved OS remained significant on multivariate analysis independent of other adverse factors, including IPI, and was validated in an independent cohort. Our findings suggest that SAMHD1 expression mediates doxorubicin resistance and may be an important prognostic biomarker in advanced, higher-risk DLBCL patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinLymphoma, Large B-Cell, DiffuseDrug Resistance, NeoplasmSAM Domain and HD Domain-Containing Protein 1HumansFemaleMaleMiddle AgedAgedPrognosisAdultAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCell Line, TumorKaplan-Meier EstimateAged, 80 and over

Substanzen

DoxorubicinSAM Domain and HD Domain-Containing Protein 1SAMHD1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
  • Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Department of Biostatistics and Bioinformatics, Rollins School of Public Health and Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.

ORCID-Profile: Waaqo Daddacha, Dominique Monroe, William S Dynan, Baek Kim, David S Yu

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NIH
  • NCI
  • NIAID

Zitieren

APA

Daddacha, W., Monroe, D., Schlafstein, A. J., Withers, A. E., Thompson, E. B., Danelia, D., Luong, N. C., Sesay, F., Rath, S. K., Usoro, E. R., Essien, M. E., Jung, A. T., Jiang, J. G., Hu, J., Mahboubi, B., Williams, A., Steinbeck, J. E., Yang, X., Buchwald, Z. S., …, & Yu, D. S. (2024). SAMHD1 expression contributes to doxorubicin resistance and predicts survival outcomes in diffuse large B-cell lymphoma patients. NAR Cancer. https://doi.org/10.1093/narcan/zcae007

Vancouver

Daddacha W, Monroe D, Schlafstein AJ, Withers AE, Thompson EB, Danelia D, et al. SAMHD1 expression contributes to doxorubicin resistance and predicts survival outcomes in diffuse large B-cell lymphoma patients. NAR Cancer. 2024. doi:10.1093/narcan/zcae007

BibTeX
@article{Daddacha2024,
  author = {Daddacha, Waaqo and Monroe, Dominique and Schlafstein, Ashley J and Withers, Allison E and Thompson, Elizabeth B and Danelia, Diana and Luong, Nho C and Sesay, Fatmata and Rath, Sandip K and Usoro, Edidiong R and Essien, Mark E and Jung, Andrew T and Jiang, Jinmeng G and Hu, Jiaxuan and Mahboubi, Bijan and Williams, Arilyn and Steinbeck, Julia E and Yang, Xiaofeng and Buchwald, Zachary S and Dynan, William S and Switchenko, Jeffrey M and Kim, Baek and Khan, Mohammad K and Jaye, David L and Yu, David S},
  title = {SAMHD1 expression contributes to doxorubicin resistance and predicts survival outcomes in diffuse large B-cell lymphoma patients},
  journal = {NAR Cancer},
  year = {2024},
  doi = {10.1093/narcan/zcae007}
}
Kostenlos starten →